NCT00447213 - A Study for Patients With Type 1 Diabetes Mellitus | Biotech Hunter

Enrollment

70

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG

Insulin glargine

Patient specific, injected, daily, 24 weeks

DRUG

Human Insulin Inhalation Powder

patient specific dose, inhaled, before meals,12 weeks

DRUG

Injectable Insulin

Patient specific dose,injected, before meals, 12 weeks

Trial Locations (5)

104

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei

333

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taoyuan District

500

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua

235-0045

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa

160-0023

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo